Your English writing platform
Discover LudwigExact(15)
PIB-PET scans were negative in three patients with pathologically confirmed CBD, one with progressive supranuclear palsy (PSP) and one with both Pick's disease and LBD.> -wrap-foot> aPatient 13 had evidence of AD and CBD pathology, but AD was the predominant pathology.
Perhaps the most important role biomarkers will have, and the most needed at this time, lies in the identification of individuals who are cognitively normal, and yet have evidence of AD pathology (i.e. preclinical AD).
Probable AD dementia meets clinical diagnostic criteria without supporting biomarker evidence of AD.
In aging, only 10% of subjects over 65 will have clinical or histological evidence of AD [ 13].
These criteria include in vivo evidence of AD pathology, requiring one of the CSF biomarker tests, amyloid PET imaging, or genetic tests, in addition to clinical criteria [ 1].
Three main categories are proposed: probable AD dementia, possible AD dementia (atypical clinical presentation), and probable or possible AD dementia with evidence of AD pathophysiological process.
Similar(45)
We present evidence of AD-induced changes in global brain functional connectivity specifically affecting long-distance connectivity.
Goldstein et al.'s study was the first to discover evidence of AD-associated pathology outside the brain.
They acknowledge that 'the definitive studies to determine whether the majority of asymptomatic individuals with evidence of AD-P are indeed destined to develop AD dementia... will likely take more than a decade to fully accomplish' ([ 3], p. 11).
Extending the diagnosis of AD to include individuals with mild cognitive impairment and even normal cognition when there is biomarker evidence of AD-type pathophysiology might facilitate the development of disease-modifying drugs for the treatment of individuals most likely to respond.
The AD group consisted of patients with probable AD with a high level of evidence of an AD pathophysiologic process and patients with mild cognitive impairment with a high likelihood of an underlying AD process.
Write better and faster with AI suggestions while staying true to your unique style.
Since I tried Ludwig back in 2017, I have been constantly using it in both editing and translation. Ever since, I suggest it to my translators at ProSciEditing.

Justyna Jupowicz-Kozak
CEO of Professional Science Editing for Scientists @ prosciediting.com